New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?

被引：15

作者：

Hoffman-Censits, Jean ^{[1
,2
]}

Lombardo, Kara ^{[3
,4
]}

McConkey, David ^{[5
,6
]}

Hahn, Noah M. ^{[1
,2
]}

Bashir, Babar ^{[7
]}

Kelly, Wm Kevin ^{[7
,8
]}

Johnson, Burles ^{[1
]}

Matoso, Andres ^{[9
,10
,11
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Dept Med Oncol, Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21218 USA

[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Dept Urol, Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21218 USA

[3] Johns Hopkins Univ, Dept Urol, Baltimore, MD USA

[4] Johns Hopkins Univ, Greenberg Bladder Canc Inst, Baltimore, MD USA

[5] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA

[6] Johns Hopkins Greenberg Bladder Canc Inst, James Buchanan Brady Urol Inst, Baltimore, MD USA

[7] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Med Oncol, Philadelphia, PA 19107 USA

[8] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Urol, Philadelphia, PA 19107 USA

[9] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA

[10] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA

[11] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2021年 / 39卷 / 10期

关键词：

Enfortumab vedotin; Nectin-4; Bladder cancer; Upper tract urothelial cancer;

D O I：

10.1016/j.urolonc.2021.05.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum-and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an anti-body-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV. (C) 2021 Published by Elsevier Inc.

引用

页码：619 / 622

页数：4

共 16 条

[1] Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC). [J].

Adib, Elio ;

Jain, Rohit K. ;

Skelton, William Paul ;

Freeman, Dory ;

Curran, Catherine ;

Akl, Elie W. ;

Nassar, Amin ;

Ravi, Praful ;

Mantia, Charlene ;

Merchan, Jaime R. ;

Tan, Winston ;

Plastini, Trisha M. ;

Choueiri, Toni K. ;

Sonpavde, Guru .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[2] EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. [J].

Balar, Arjun Vasant ;

McGregor, Bradley Alexander ;

Rosenberg, Jonathan E. ;

van der Heijden, Michiel Simon ;

Park, Se Hoon ;

Lee, Jae-Lyun ;

Harrison, Michael Roger ;

Heath, Elisabeth, I ;

Stein, Mark N. ;

Loriot, Yohann ;

Necchi, Andrea ;

Steinberg, Joyce Leta ;

Liang Shang-Ying ;

Kim, Eric ;

Trowbridge, Janet ;

Campbell, Mary S. ;

Petrylak, Daniel Peter ;

Yu, Evan Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[3] Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma [J].

Chen, Robert ;

Herrera, Alex ;

Hou, Jessie ;

Chen, Lu ;

Wu, Jun ;

Guo, Yuming ;

Synold, Timothy W. ;

Ngo, Vu N. ;

Puverel, Sandrine ;

Mei, Matthew ;

Popplewell, Leslie ;

Yi, Shuhua ;

Song, Joo Y. ;

Tao, Shu ;

Wu, Xiwei ;

Chan, Wing C. ;

Forman, Stephen J. ;

Kwak, Larry W. ;

Rosen, Steven T. ;

Newman, Edward M. .

CLINICAL CANCER RESEARCH, 2020, 26 (05) :1034-1044

[4] CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin [J].

Chen, Robert ;

Hou, Jessie ;

Newman, Edward ;

Kim, Young ;

Donohue, Cecile ;

Liu, Xueli ;

Thomas, Sandra H. ;

Forman, Stephen J. ;

Kane, Susan E. .

MOLECULAR CANCER THERAPEUTICS, 2015, 14 (06) :1376-1384

[5] Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. [J].

Chu, Carissa ;

Sjostrom, Martin ;

Egusa, Emily A. ;

Gibb, Ewan ;

Badura, Michelle L. ;

Koshkin, Vadim S. ;

Stohr, Bradley A. ;

Meng, Maxwell ;

Pruthi, Raj ;

Friedlander, Terence W. ;

Lotan, Yair ;

Black, Peter C. ;

Porten, Sima P. ;

Feng, Felix Y. ;

Chou, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[6]

Hoffman-Censits JH, APPL IMMUNOHISTO M M, V9000

[7] Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. [J].

Koshkin, Vadim S. ;

Sun Yilun ;

Freeman, Dory ;

Osterman, Chelsea K. ;

Su, Christopher ;

Natesan, Divya ;

Khaki, Ali Raza ;

Makrakis, Dimitrios ;

Jain, Jayanshu ;

Olsen, Anders ;

Basu, Arnab ;

Barata, Pedro C. ;

Zakharia, Yousef ;

Bilen, Mehmet Asim ;

Emamekhoo, Hamid ;

Davis, Nancy B. ;

Milowsky, Matthew, I ;

Kilari, Deepak ;

Sonpavde, Guru ;

Alva, Ajjai Shivaram .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[8] Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma [J].

Loriot, Y. ;

Necchi, A. ;

Park, S. H. ;

Garcia-Donas, J. ;

Huddart, R. ;

Burgess, E. ;

Fleming, M. ;

Rezazadeh, A. ;

Mellado, B. ;

Varlamov, S. ;

Joshi, M. ;

Duran, I. ;

Tagawa, S. T. ;

Zakharia, Y. ;

Zhong, B. ;

Stuyckens, K. ;

Santiago-Walker, A. ;

De Porre, P. ;

O'Hagan, A. ;

Avadhani, A. ;

Siefker-Radtke, A. O. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :338-348

[9] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma [J].

Powles, Thomas ;

Rosenberg, Jonathan E. ;

Sonpavde, Guru P. ;

Loriot, Yohann ;

Duran, Ignacio ;

Lee, Jae-Lyun ;

Matsubara, Nobuaki ;

Vulsteke, Christof ;

Castellano, Daniel ;

Wu, Chunzhang ;

Campbell, Mary ;

Matsangou, Maria ;

Petrylak, Daniel P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1125-1135

[10]

Robertson AG, 2017, CELL, V171, P540, DOI [10.1016/j.cell.2017.09.007, 10.1016/j.cell.2018.07.036]

← 1 2 →